Article
Risk stratification in nonmuscle-invasive bladder cancer (CME)
By risk-stratifying nonmuscle-invasive bladder cancers, urologists can characterize pathologic subtypes and develop individualized treatment and surveillance strategies.(CME)
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Justin Dubin, MD, on leveraging digital tools to improve patient buy-in
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Mina Fam, MD, on managing expectations around testosterone replacement therapy
Justin Dubin, MD, on the role for AI in patient education
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
Related Content
